Pharmacokinetic study of vorinostat in cutaneous T cell lymphoma patients
10.13699/j.cnki.1001-6821.2015.21.010
- VernacularTitle:伏立诺他在皮肤 T细胞淋巴瘤患者的药代动力学研究
- Author:
Jing ZHENG
1
;
Yong-Ping QIN
;
Jia MIAO
;
Li ZHANG
;
Wen LIU
;
Shi-Qing SHU
;
Ying WANG
;
Xiao-Hong ZHU
Author Information
1. 四川大学 华西医院 I 期临床研究室
- Keywords:
vorinostat;
cutaneous T -cell lymphoma;
single dose;
pharmacokinetic
- From:
The Chinese Journal of Clinical Pharmacology
2015;(21):2118-2120
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the pharmacokinetic( PK) charac-teristics of vorinostat in cutaneous T -cell lymphoma ( CTCL ) patients after a single dose.Methods Two cases of CTCL patients were orally administered of vorinostat capsules at 200 mg or 400 mg once after break-fast.The 3 mL blood samples were collected pre-dose and at different time points.Vorinostat ( SHA ) , M2 metabolites ( M2 ) and the internal standard d5-vorinostat( d5-SHA) in serum were measured by HPLC-MS/MS method.WinNonlin 6.1 software was used to calculate the non-compartment pharmacokinetic parameters.Results After a single dose of oral administration of 200 mg and 400 mg vorinostat capsule, Cmax were 262.95 and 257.46 ng? mL-1 , t1/2 were 1.86 and 2.52 h, tmax were 3.00 and 4.00 h, AUC0-t were 638.13 and 1503.14 ng? mL-1? h for SHA, respectively.Cmax were 450.88 and 652.70 ng? mL-1 , t1/2 were 80.21 and 14.14 h, tmax was 4.00 h, AUC0-t were 2292.03 and 4848.29 ng? mL-1? h for M2, respectively.It was safe for the two patients to use vorinostat capsule, and there was no adverse reactions.Conclusion The individual disposition of vorinostat had a large different.
